An analysis of the Swiss MS Cohort has found that routine monitoring of serum biomarkers can aid in predicting progression independent of relapse activity (PIRA) in patients during B cell-depleting therapy (Benkert et al. Ann Neurol 2025;97:104-115). Read More
Neurology
New advances in epilepsy: highlights from AES 2024
December 17, 2024Fluid biomarkers in MS – the year in review
November 25, 2024High-efficacy DMTs in MS – the year in review
November 14, 2024Cenobamate as adjunctive therapy for partial-onset seizures: a review
October 25, 2024SPECIAL REPORT
Mechanism of action
Efficacy and safety studies
Use of adjunctive cenobamate in practice
Quick poll on epilepsy management
Submit your answers to reveal how your colleagues voted (respondents remain anonymous)